Overview of Dr. Postow
Dr. Michael Postow is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from New York University Grossman School of Medicine and has been in practice 12 years. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.
Office
160 East 53rd Street
New York, NY 10022
Education & Training
New York University School of MedicineClass of 2007
Certifications & Licensure
FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2019 - 2025
NY State Medical License 2010 - 2025
MA State Medical License 2009 - 2012- American Board of Internal Medicine Medical Oncology
Clinical Trials
- CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma Start of enrollment: 2022 Mar 11
Roles: Principal Investigator, Contact
- A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma Start of enrollment: 2023 Jun 09
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis.Joan Shang, Diane Marie Del Valle, Graham J Britton, K R Mead, Urvija Rajpal
The Journal of Experimental Medicine. 2025-01-06 - Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab + Ipilimumab in CheckMa...Raymond Y Huang, Gilbert Youssef, Thomas Nelson, Patrick Y Wen, Peter Forsyth
Journal of Clinical Oncology. 2025-01-03 - Intratumoral vidutolimod in combination with PD-1 blockade in locoregionally advanced melanoma.James W Smithy, Michael A Postow
Cancer Cell. 2024-11-11
Journal Articles
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainKim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine
- Marked Response of a Hypermutated Adrenocorticotropic Hormone-Secreting Pituitary Carcinoma to Ipilimumab and NivolumabMichael Postow, Viviane Tabar, T Jonathan Yang, John Cuaron, Jinru Shia, Lisa M DeAngelis, The Journal of Clinical Endocrinology and Metabolism
- Melanoma Brain Metastases Treated with Stereotactic Radiosurgery and Concurrent Pembrolizumab Display Marked Regression; Efficacy and Safety of Combined TreatmentJedd D Wolchok, Kathryn Beal, Yoshiya Yamada, Michael A Postow, BioMed Central
Lectures
- Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiotherapy (RT) in patients with metastatic melanoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Treatment of Advanced Melanoma After Progression on PD-1 Blockade2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
- Melanoma and Other Skin Cancers. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 1)2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018
Press Mentions
Timing of Melanoma Immunotherapy Could Be Key to Outcomes: StudyMarch 6th, 2023- Melanoma Research Alliance Announces $8.1 Million in Research AwardsApril 27th, 2021
- How Should We Evaluate the Benefit of Immunotherapy Combinations?December 10th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
